New clinical data highlights optimized outcomes achieved with the ALLY® System across toric IOL and arcuate incision treatment strategies.

91-98% of eyes achieved residual cylinder ≤ 0.50 D using both IntelliAxis® and ALLY's AKs.¹⁻³

More than 70% of cataract patients present with astigmatism ≥ 0.50 D, making astigmatism correction an important factor in achieving high-quality visual outcomes.⁴ This white paper summarizes findings from multiple surgeons, showcasing how ALLY supports precise astigmatism management across a range of treatment approaches.

Learn how ALLY supports confident astigmatism correction!

1. Stephenson D. Intraoperative Aberrometry Analysis of Iris Registration-Guided Laser Capsular Marks to Guide Toric IOL Alignment. Paper presented at ASCRS-ASOA Annual Meeting: Washington, D.C.; April 10-13, 2026.
2. Wörtz G. Comparison of Arcuate Keratotomy and Toric Intraocular Lenses for Managing Low Astigmatism During Cataract Surgery. Paper presented at ASCRS-ASOA Annual Meeting: Washington, D.C.; April 10-13, 2026.
3. Balest Z, Blehm C. Outcomes of Astigmatism Management with Robotic Laser Refractive Capsulorhexis Markings for Toric IOL Alignment or Arcuate Incisions. Paper presented at ASCRS-ASOA Annual Meeting: Washington, D.C.; April 10-13, 2026.
4. Shallhorn SC, Hettinger KA, Pelouskova M, et al. Effect of residual astigmatism on uncorrected visual acuity and patient satisfaction in pseudophakic patients. J Cataract Refract Surg.2021;47(8):991-998.

© 2026 LENSAR, Inc. All rights reserved. LENSAR, the LENSAR logo, Streamline, IntelliAxis, IntelliAxis Refractive Capsulorhexis, ALLY, the ALLY logo, ALLY Robotic Cataract Laser System, the ALLY Robotic Cataract Laser System logo and ALLY Robotic Laser Cataract Surgery are registered trademarks and Intelligent Incisions, Adaptive Intelligence, Robotic Laser Cataract Surgery, and the Robotic LCS logo are trademarks of LENSAR, Inc. All other trademarks are the property of their respective owners.

Sponsored By